Does Low-Dose Aspirin Improve Outcome in In Vitro Fertilisation/Intra Cytoplasmatic Sperm Injection (IVF/ICSI)?

This study has been completed.
Information provided by:
University Hospital, Ghent Identifier:
First received: March 20, 2008
Last updated: March 26, 2008
Last verified: March 2008
To investigate the effect of daily administration of low-dose aspirin, compared to placebo, on IVF and ICSI outcome.

Condition Intervention Phase
Drug: aspirin
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Does Low-Dose Aspirin Improve Outcome in IVF/ICSI? A Prospective, Randomized, Double Blind Placebo Controlled Trial

Resource links provided by NLM:

Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Number of oocytes retrieved [ Designated as safety issue: No ]
  • Clinical pregnancy rate per embryo transfer [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Live birth rate per cycle [ Designated as safety issue: No ]

Enrollment: 201
Study Start Date: April 2000
Study Completion Date: December 2007
Arms Assigned Interventions
Experimental: 1
oral administration of aspirin 100 mg
Drug: aspirin
oral administration of aspirin 100 mg
Placebo Comparator: 2
oral administration of placebo
Drug: placebo
oral administration of placebo


Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Dutch-speaking women
  • Starting a first or second IVF/ICSI cycle

Exclusion Criteria:

  • Women suffering from

    • platelet dysfunction
    • thrombopenia
    • gastro-intestinal ulcers
    • recurrent gastritis
    • aspirin hypersensitivity
  • Women on treatment with anticoagulants or aspirin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00644085

University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Principal Investigator: Marc Dhont, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kaatje Dirckx, MD, University Hospital Ghent Identifier: NCT00644085     History of Changes
Other Study ID Numbers: 99/191 
Study First Received: March 20, 2008
Last Updated: March 26, 2008
Health Authority: Belgium: Institutional Review Board

Keywords provided by University Hospital, Ghent:

Additional relevant MeSH terms:
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents processed this record on May 26, 2016